Amoxicillin for chest cold

Drugs that may cause interactions Amoxicillin Penicillin methotrexate x x allopurinol x probenecid x x warfarin x x birth control pills x x mycophenolate x x other antibiotics x x.

Before starting

amoxicillin

Keep the following precautions in mind if your doctor prescribes amoxicillin or penicillin. Certain medications can make certain health conditions or diseases worse. For example, if you have severe kidney disease, you should talk with your doctor before taking amoxicillin or penicillin. Also ask your doctor if you can use amoxicillin and penicillin safely if you have severe allergies or asthma. You’re at higher risk of side effects from these medications.

If you know that you’re allergic to penicillin, you shouldn’t take penicillin or penicillin antibiotics such as amoxicillin.

The reverse is also true: If you’re allergic to amoxicillin, you shouldn’t take penicillin or other penicillin antibiotics.

In addition, if you’re allergic to cephalosporin antibiotics, you’re at risk for an allergic reaction to penicillin antibiotics.

Symptoms of an allergic reaction to amoxicillin or penicillin can include: trouble breathing hives rash swelling of your lips or tongue.

If you have any of these symptoms, stop taking the antibiotic and call your doctor right away. If your symptoms are severe, call 911 or go to the nearest emergency room.

Antibiotics such as amoxicillin or penicillin can cause severe diarrhea.

Sometimes the diarrhea is linked with an infection by a type of bacteria called Clostridium difficile ( C. diff infection can include: watery diarrhea that is severe or lasts more than two days cramping in your abdomen dehydration (low fluid levels in your body), which typically doesn’t cause symptoms inflammation of the colon, which typically doesn’t cause symptoms weight loss. If you have these symptoms, call your doctor right away.

If your amoxicillin plus clavulanate symptoms are severe, go to the nearest emergency room.

You can drink alcohol while taking either amoxicillin or penicillin.

There are no special precautions against using these

drugs

Still, there are other things to consider about drinking while treating an infection. For more information,

read

Archivos de

Bronconeumologia

Therefore, the submission of manuscripts written in either Spanish or English is welcome.

Translators working for the Journal are in charge of the corresponding translations.

Manuscripts will be submitted electronically using the following web site: https://www.editorialmanager.com/ARBR/, link which is also accessible through the main web

page

Furthermore, the Journal is also present in Twitter and Facebook. The Journal expresses the voice of the Spanish Respiratory Society of Pulmonology and Thoracic Surgery (SEPAR) as well as that of other scientific societies such as the Latin American Thoracic Society (ALAT) and the Iberian American Association of Thoracic Surgery (AICT).

Authors are also welcome to submit their articles to the Journal's open access companion

title

Indexed in: Current Contents/Clinical Medicine, JCR SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, SCOPUS, IBECS. Follow us: The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two receding years. © Clarivate Analytics, Journal Citation Reports 2020. CiteScore measures average citations received per document published.

SRJ is a prestige metric based on the idea that not all citations are the same.

SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field. Community-acquired pneumonia (CAP) is a common infection with high morbidity.

The exact incidence of CAP is not known because it is not a reportable disease, but it is estimated that it could range between 1.6 and 13.4 per 1000 people per year.

1-4 Since the morbidity and mortality of CAP are high and the disease represents a

major

The treatment strategies recommended in the guidelines published by different international institutions are, however, controversial and difficult to standardize for all patients and across different geographical areas.

5-8 One of the main reasons for modifying the established regimens of empirical therapy is the variation in the susceptibility patterns of the most common pathogens, particularly Streptococcus pneumoniae and Haemophilus influenzae .

Relatively few studies have been carried out in Latin America on the etiology of CAP and the patterns of antibiotic susceptibility of its causal agents.

In 2 studies carried out in Brazil and Argentina, a high prevalence of atypical pathogens was observed.

9,10 It is also worth noting that the scant data available on resistance indicates that the resistance of the pneumococcus to penicillin may be as high as 25%. It is important to obtain data on the etiology of CAP and the patterns of antibiotic susceptibility across different geographical areas, as well as information concerning the efficacy of new antibiotics in this context.

This paper brings together data

from

This study was conducted with approval from the ethics committees in each of the participating countries.

Informed consent was obtained from each patient prior to entry into the study.

Adult patients (?18 years of age) presenting with CAP of suspected pneumococcal origin were enrolled in the study.

Patients were classified as having CAP if they presented with fever (rectal temperature >38.5?C or oral temperature >38.0?C), radiologic evidence of pneumonia, and at least one of the following signs or symptoms: purulent sputum, dyspnea/tachypnea (>20 breaths/min), and/or auscultatory findings indicative of pulmonary consolidation. The etiology was suspected of being pneumococcal if the patient presented with at least 1 of the following findings: rapid onset of symptoms (?48 hours), high fever (rectal temperature ?39°C, or oral temperature ?38.5°C) accompanied by rigors or chills, pleuritic chest pain, chest radiograph showing an infiltrate, or the presence of Gram-positive cocci on direct sputum stain.

Patients were excluded from the study if they presented with a history of hypersensitivity to quinolones or penicillins, prior history of tendinopathy associated with quinolones, or suspected aspiration pneumonia.

Patients were not admitted if they had a serious respiratory infection requiring parenteral therapy or mechanical ventilation, a concurrent disease considered likely to interfere with the clinical course of the pneumonia, or neutropenia (neutrophil count 3.0 mg/dL [>265 µmol/L]), hepatic disease (baseline alanine aminotransferase or aspartate aminotransferase and/or total bilirubin level more than 3 times the upper limit of normal), serious heart failure, or a life-threatening disease and life expectation of 48 hours before the onset of pneumonia were not eligible for entry into the study.

Also excluded were patients who had received a systemic

antibiotic

The decision whether or not to hospitalize patients was left to the discretion of the investigator.

Adverse events were recorded at every visit, and were classified by the investigator as to their severity and relationship to the medication being studied. Two blood samples were obtained for cultures from each patient before treatment was started.

At visit 1, samples of bronchopulmonary secretions were also collected for culture.

A sample of sputum or bronchial material was obtained by 1 of the following methods: bronchoalveolar lavage (BAL) or protected specimen brush in a telescoping catheter, transtracheal aspirate, or pleural fluid by aspiration of the effusion.

Gram's stains were performed on all sputum samples and all bronchial specimens.

The quality of the sputum and of the nasotracheal

and

The cut points for BAL and protected brush specimens were 10 4 cfu/mL and 10 3 amoxicillin 800 cfu/mL, respectively.

Antibiotic susceptibility (minimum inhibitory concentration values [MIC]-90) was determined for Gram-positive and Gram-negative pathogens using the E-test (AB biodisk: Solna, Sweden) for both moxifloxacin and amoxicillin as well as for clarithromycin, cefuroxime, and clavulanic amoxicillin-acid. Blood and urine samples were collected at visit 1 for detection of the pneumococcal antigen by counterimmuno-electrophoresis. Blood samples for serological testing for Legionella pneumophila, Mycoplasma pneumoniae, Chlamydia pneumoniae, Chlamydia psittaci and Coxiella burnetii were collected at visits 1 and 4.

All the serological tests were carried out at a centralized reference laboratory (Glarif Cerba, Baillet en France, France).

All the patients who were enrolled in the study and received at least 1 dose of the study medication were evaluated as patients with intention to treat (ITT population). Patients who were given the study medication for a minimum of 48 hours (in the case of clinical failure) or 5 full days (in the case of clinical success) were included in the evaluable population (EP).

Efficacy analyses were performed on both populations. The primary efficacy variable was clinical response 3 to 5 days after completion of treatment (visit 3).

The patient was considered to be cured when the acute signs and symptoms related to the infection had disappeared, or had improved so much that the patient no longer required additional or alternative antibiotic therapy.

Treatment was considered a failure when there was an insufficient reduction of the signs and symptoms of infection such that the patient required additional or alternative antibiotic therapy or died as a consequence of the primary diagnosis (pneumonia).

The outcome was classified as undetermined when clinical assessment was not possible (premature withdrawal after less than 2 days of treatment, patient unavailable for evaluation, etc). The early failures (at visit 2) were also classified as failures at visits 3 and 4, and the failures at visit 3 were also considered

failures

failure

with